Citizens JMP Maintains Buy Rating on Artivion, Adjusts Price Target
Analyst Daniel Stauder of Citizens JMP has maintained a 'Buy' rating on Artivion (AORT) while lowering the price target from $48 to $42.
Stocks · News reference
Artivion, Inc. has scheduled the release of its third quarter 2026 financial results for November 5, 2026, following the market close.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analyst Daniel Stauder of Citizens JMP has maintained a 'Buy' rating on Artivion (AORT) while lowering the price target from $48 to $42.
The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.
Artivion, Inc. announced its financial results for the third quarter of 2026, reporting $123.8 million in revenue and narrowing its full-year 2026 financial outlook.
Artivion, Inc. announced its participation in the Stifel 2026 Healthcare Conference and the 20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum in November 2026.
Jefferies analyst Michael Sarcone initiates coverage on Artivion (NYSE:AORT) with a Buy rating and announces Price Target of $31.
Artivion (NYSE:AORT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our